EFFECT OF A 5-HT3 RECEPTOR ANTAGONIST ON RESPIRATORY DRIVE IN SPONTANEOUSLY BREATHING MECHANICALLY VENTILATED PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS): A PILOT PROOF-OF-CONCEPT CROSSOVER NON-RANDOMIZED CONTROLLED TRIAL

Registry ID

2023-2502

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CIUSSS DU NORD-DE-L'ILE-DE-MONTRÉAL - HÔPITAL DU SACRÉ-COEUR DE MONTRÉAL.

Start date

2022-11-17

Last update

2022-06-16

Conditions

• ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Related clinical trials

• A RANDOMIZED, CONTROLLED, BLINDED, PARALLEL GROUP STUDY OF THE SAFETY AND EFFICACY OF AEROFACT¿ (SF-RI 1 SURFACTANT FOR INHALATION COMBINED WITH A DEDICATED DELIVERY SYSTEM) IN PRETERM INFANTS WITH RESPIRATORY DISTRESS SYNDROME
• SURFACTANT ADMINISTRATION BY SUPRAGLOTTIC AIRWAY (THE SURFSUP TRIAL)
• EXTEND: NOVEL OXYGEN THERAPEUTIC NANO2 FOR MILD RESPIRATORY DISTRESS IN PHASE IB AND ARDS IN PHASE II TRIALS

View on source registry